PMID- 35045651
OWN - NLM
STAT- MEDLINE
DCOM- 20220121
LR  - 20220201
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 42
IP  - 11
DP  - 2021 Nov 14
TI  - [The diagnostic value of whole blood Epstein-Barr virus DNA load in 
      lymphoproliferative diseases after allogeneic hematopoietic stem cell 
      transplantation].
PG  - 904-910
LID - 10.3760/cma.j.issn.0253-2727.2021.11.004 [doi]
AB  - Objectives: To investigate the diagnostic value of whole blood quantitative PCR 
      for DNA load of Epstein-Barr virus (EBV) in post-transplant lymphoproliferative 
      disease (PTLD) after allogeneic hematopoietic stem cell transplantation 
      (allo-HSCT) . Methods: A total of 694 patients with hematologic diseases who 
      underwent allo-HSCT at the Hematology Department of Peking University First 
      Hospital from April 2004 to April 2019 were included, and their data were 
      retrospectively analyzed. Results: 1 in circleAmong the 694 cases, 29 cases (22 males and 7 
      females, with a median age of 22 (1-52) years) developed PTLD after allo-HSCT 
      with a cumulative incidence of 4.2% and a median onset time of 2.1 (0.8-20.6) 
      months. 2 in circle Univariate analysis showed that age<30 years, diagnosis with aplastic 
      anemia, human leukocyte antigen (HLA) mismatch, use of antithymocyte globulin 
      (ATG) in preconditioning regimens, and EBV reactivation were the risk factors for 
      the occurrence of PTLD. Multivariate analysis showed that EBV reactivation was an 
      independent risk factor for the occurrence of PTLD. 3 in circleFurther analysis of EBV 
      reactivation cases showed that the peak value of EBV-DNA load was significantly 
      higher in the PTLD group than that in the non-PTLD group (P<0.001) and the 
      incidence of PTLD increased with the increase of EBV-DNA load. Receiver operating 
      characteristic (ROC) curve analysis indicated that PTLD was more likely to be 
      diagnosed when the EBV-DNA load was >1.19x10(6) copies/ml (sensitivity 0.800 and 
      specificity 0.768) . 4 in circleAll patients with PTLD received rituximab-based treatment, 
      with an overall response rate of 86.2% and an overall survival rate of 54.3%. 
      Conclusion: The PTLD occurrence after allo-HSCT is highly correlated with EBV 
      reactivation, and the higher the EBV-DNA load, the greater the risk of PTLD 
      occurrence. The dynamic monitoring of EBV-DNA load plays an important role in 
      predicting PTLD occurrence.
FAU - Niu, Y Y
AU  - Niu YY
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, China 
      Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical 
      Sciences, Taiyuan 030032, China.
FAU - Dong, Y J
AU  - Dong YJ
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Yin, Y
AU  - Yin Y
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Xu, W L
AU  - Xu WL
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Liang, Z Y
AU  - Liang ZY
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Wang, Q
AU  - Wang Q
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Li, Y
AU  - Li Y
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Liu, W
AU  - Liu W
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Ou, J P
AU  - Ou JP
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Ren, H Y
AU  - Ren HY
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, 
      China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adult
MH  - DNA, Viral
MH  - *Epstein-Barr Virus Infections
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Herpesvirus 4, Human/genetics
MH  - Humans
MH  - *Lymphoproliferative Disorders/diagnosis/etiology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Viral Load
MH  - Young Adult
PMC - PMC8763583
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - EBV reactivation
OT  - Lymphoproliferative disorders
EDAT- 2022/01/21 06:00
MHDA- 2022/01/22 06:00
PMCR- 2021/11/01
CRDT- 2022/01/20 01:32
PHST- 2022/01/20 01:32 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/01/22 06:00 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - cjh-42-11-904 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2021.11.004 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2021 Nov 14;42(11):904-910. doi: 
      10.3760/cma.j.issn.0253-2727.2021.11.004.